Ribosome Inactivating Proteins, Type 1
Research News and Information

Sunday, November 22, 2009

Transition state analogues rescue ribosomes from saporin-L1 ribosome inactivating protein.

18 Oct 2009 Ribosome inactivating proteins (RIPs) catalyze the hydrolytic depurination of one or more adenosine residues from eukaryotic ribosomes. Depurination of the ribosomal sarcin-ricin tetraloop (GAGA) causes inhibition of protein synthesis and cellular ... Read more...

Nitrous oxide-induced analgesia does not influence nitrous oxide's immobilizing requirements.

29 Sep 2009 BACKGROUND: Nitrous oxide (N(2)O) acts on supraspinal noradrenergic neurons to produce analgesia, but it is unclear if analgesia contributes to N(2)O's immobilizing effects. We tested the hypothesis that N(2)O minimum alveolar anesthetic ... Read more...

Immunotoxin-induced ablation of melanopsin retinal ganglion cells in a non-murine mammalian model.

8 Sep 2009 In mammals, non-image-forming visual functions, including circadian photoentrainment and the pupillary light reflex, are thought to be mediated by the combination of rods, cones, and the melanopsin-expressing intrinsically photosensitive retinal ... Read more...

Latest indexed articles for 'Ribosome Inactivating Proteins, Type 1'

These are the very latest articles for this heading:

• Transition state analogues rescue ribosomes from saporin-L1 ribosome inactivating protein. 18 Oct 2009
• Nitrous oxide-induced analgesia does not influence nitrous oxide's immobilizing requirements. 29 Sep 2009
• Immunotoxin-induced ablation of melanopsin retinal ganglion cells in a non-murine mammalian model. 8 Sep 2009
• Inhibition of tumor growth by targeted toxins in mice is dramatically improved by saponinum album in a synergistic way. 30 Aug 2009
• The neurokinin-1 receptor modulates the methamphetamine-induced striatal apoptosis and nitric oxide formation in mice. 11 Aug 2009
• Cellular basis of itch sensation. 4 Aug 2009
• Cell transplantation: a future therapy for narcolepsy? 30 Jul 2009
• Hypocretin-2 saporin lesions of the ventrolateral periaquaductal gray (vlPAG) increase REM sleep in hypocretin knockout mice. 20 Jul 2009
• Structure/function studies on two type 1 ribosome inactivating proteins: Bouganin and lychnin. 14 Jul 2009
• Enhancement of saporin cytotoxicity by Gypsophila saponins--more than stimulation of endocytosis. 14 Jul 2009
• Immunotoxic depletion of microglia in mouse hippocampal slice cultures enhances ischemia-like neurodegeneration. 8 Jul 2009
• A cholinergic-dependent role for the entorhinal cortex in trace fear conditioning. 22 Jun 2009
• Effect of voluntary running on adult hippocampal neurogenesis in cholinergic lesioned mice. 3 Jun 2009
• Enhancement of toxicity of saporin-based toxins by Gypsophila saponins--kinetic of the saponin. 31 May 2009
• Ablation of least shrew central neurokinin NK1 receptors reduces GR73632-induced vomiting. 30 May 2009
• Stress-induced curcin-L promoter in leaves of Jatropha curcas L. and characterization in transgenic tobacco. 26 May 2009
• The basal forebrain cholinergic system is required specifically for behaviorally mediated cortical map plasticity. 4 May 2009
• Cognitive performances of cholinergically depleted rats following chronic donepezil administration. 29 Apr 2009
• Effects of chronic donepezil treatment and cholinergic deafferentation on parietal pyramidal neuron morphology. 29 Apr 2009
• Substance P neurotransmission and violent aggression: the role of tachykinin NK(1) receptors in the hypothalamic attack area. 30 Mar 2009

See a longer list of these articles.

Technical information about 'Ribosome Inactivating Proteins, Type 1'

Definition: Ribosome inactivating proteins consisting of only the toxic A subunit, which is a polypeptide of around 30 kDa.

Registry Number: 0

Descriptor UI: D054789

Alternative terms: Ribosome Inactivating Proteins, Type 1;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; deficiency; diagnostic use; drug effects; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; physiology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; ultrastructure; urine; chemistry; contraindications;

Tree Number: D08.811.277.450.430.700.500; D12.776.765.710.500;

History Note: 2008